

PATENT

B2  
SUB 3

20. (Amended) The method of claim 17, wherein the chemokine is lymphotactin, RANTES, MIP-1-alpha, MCP-1, MCP-4, IL-8, murine KC, murine MIP2, human GCP2, human IP10, fractaline, murine LIX, MIP-1, or secondary lymphoid tissue chemokine SLC.

Please insert the following new claim:

SUB 5  
B3

28. (New) The method of claim 17, wherein the M3 protein, or homologue is a coupled protein.

**In the specification:**

Please amend page 1 of the specification to insert the following text beginning at page 1, line 19:

**Brief Description of the Drawings**

Figure 1 is a set of auto-radiographs of SDS-PAGE analysis, with molecular masses in kDa, from experiments in which soluble chemokine binding activity is produced by MHV68.

B4

Figure 2 is an auto-radiograph of another SDS-PAGE analysis from an experiment to show binding specificity of the soluble chemokine binding protein encoded by the MHV68 M3 ORF.

Figure 3 is a graph showing binding of [125I] RANTES to test (U937) cells in the presence of different amounts of MHV68-infected cell supernatants expressed as cell equivalents.

Figure 4 is a set of two graphs (4 (a) and 4 (b)) showing binding of MIP-1 alpha and IL-8 to U937 cells respectively.

Figure 5 is an auto-radiograph of SDS-PAGE analysis experiments involving binding of M3 to MIP-1 alpha and IL-8 respectively.

<PATENT>

EXPRESS MAIL LABEL NO. EL754020625US  
DATE OF DEPOSIT: July 19, 2001  
Attorney Reference Number 5673-55696  
Application Number 09/617,178

B4  
CWT  
Figure 6 is a graph showing results of inhibition experiments with M3, cultured cells and RANTES and demonstrates that M3 inhibits RANTES induced calcium flux in human PBMCs in a dose dependent manner.

Figure 7 is a set of two graphs (7(a) and 7(b)). Graph 7(a) shows that M3 inhibits MCP-1 induced migration of THP-1 cells, and graph 7 (b) shows that M3 inhibits IL-8 induced migration of neutrophils.

Figure 8 is a graph showing results of in-vivo experiments for the effect of M3 on inflammatory responses in mice.

### REMARKS

Claim 21 is canceled herein, without prejudice to renewal. Claims 17 and 20 are amended herein. No new matter is added. Reconsideration of the subject application is respectfully requested.

#### Basis for claim amendments

Support for the amending language of claim 17 can be found in the specification at page 1, line 20-21 (for functional homologues). Support for the amending language of claim 20 can be found in the specification at page 10, lines 6-7 (for secondary lymphoid tissue chemokine SLC); page 2, line 22 (for murine LIX), and in original claim 21 for MIP-1 .

Support for new claim 28 can be found in the specification at page 6, lines 7-9 (for coupled M3 proteins).

#### Arrangement of the specification

The specification was objected to for not providing a "Brief Description of the Drawings." Page 1, has been amended to insert a Brief Description of the Drawings beginning at page 1, line 18.